Sino Biopharmaceutical rises on progress of breast cancer drug

Sino Biopharmaceutical

10/02/2026 03:54

** Shares of Sino Biopharmaceutical 1177.HK rise 5.6% to HK$6.97, on track for biggest one-day pct gain since November 13

** Stock hits the highest point since January 29 on the sixth straight session of rise

** Co says its breast cancer drug TQB2102 "HER2 bispecific ADC" is undergoing phase III clinical trial to evaluate efficacy and safety of the product for injection versus investigator-selected chemotherapy in HER2-Low breast cancer

** Says enrolment of all subjects has recently been completed

** YTD, stock up 12%, the Hang Seng Biotech Index .HSBIO up 13.4%

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))